Adenovirus Type 4 And Type 7 Vaccine, Live Kit
NDC Package 51285-138-50
Package Information
Adenovirus Type 4 And Type 7 Vaccine, Live kits is adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. This formulation utilizes a kit delivery system. Marketed by Teva Women's Health Llc, this product is identified by NDC 51285-138 and is authorized under FDA application BLA125296.
Identification & Billing
- RxCUI: 1099936 - adenovirus type 4 vaccine, live 32,000 TCID50 Delayed Release Oral Tablet
- RxCUI: 1099936 - adenovirus type 4 vaccine live 32000 UNT Delayed Release Oral Tablet
- RxCUI: 1099940 - adenovirus type 7 vaccine, live 32,000 TCID50 Delayed Release Oral Tablet
- RxCUI: 1099940 - adenovirus type 7 vaccine live 32000 UNT Delayed Release Oral Tablet
- RxCUI: 1099941 - {100 (adenovirus type 4 vaccine live 32000 UNT Delayed Release Oral Tablet) / 100 (adenovirus type 7 vaccine live 32000 UNT Delayed Release Oral Tablet) } Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51285 - Teva Women's Health Llc
- 51285-138 - Adenovirus Type 4 And Type 7 Vaccine, Live
- 51285-138-50 - 1 KIT in 1 CARTON * 100 TABLET, COATED in 1 BOTTLE (51285-175-02) * 100 TABLET, COATED in 1 BOTTLE (51285-174-02)
- 51285-138 - Adenovirus Type 4 And Type 7 Vaccine, Live
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51285-138-50 identifies a specific commercial package of 1 kit in 1 carton * 100 tablet, coated in 1 bottle (51285-175-02) * 100 tablet, coated in 1 bottle (51285-174-02) of Adenovirus Type 4 And Type 7 Vaccine, Live, a vaccine label labeled by Teva Women's Health Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Women's Health Llc on September 16, 2011. The current certification is valid through December 31, 2027.
How is this Teva Women's Health Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51285013850. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.